Personalis, Inc. is a California-based cancer genomics company that helps develop cancer therapies and supports large-scale genetic research programs worldwide through sequencing and data analysis services. The company offers the NeXT Platform for data analysis of a tumor's microenvironment and immune response, ImmunoID Next for tissue tumor profiling, NeXT Liquid Biopsy for plasma tumor profiling, and NeXT Dx Test for genomic cancer profiling, among other products. Personalis serves biopharmaceutical customers, universities, non-profits, and government entities, and has partnerships with several institutions, including Mayo Clinic and Moores Cancer Center.